IDbyDNA, Inc., a San Francisco, CA-based metagenomics technology company, raised $20m in Series B financing.
The round was led by Artis Ventures with participation from Genesys Capital and others.
The company intends to use the funds to accelerate growth of its software platform into the worldwide infectious disease and microbiome testing markets and open a CLIA-approved commercial laboratory at its Salt Lake City facility.
Led by Guochun Liao, PhD, co-founder and CEO, IDbyDNA creates and utilizes novel technologies that improve the accuracy and speed of universal microorganism detection, with the potential to identify any microbe from any sample.
The Explify platform identifies more than 50,000 microorganisms and over 3,000 known common and rare pathogens. In addition to broad pathogen detection, Explify also includes features such as quantification and the ability to detect antimicrobial resistance (AMR).